Barata Rita, Saavedra Maria José, Almeida Gonçalo
National Institute of Agricultural and Veterinary Research (INIAV), 4485-655 Vila do Conde, Portugal.
Centre for the Research and Technology of Agro-Environmental and Biological Sciences (CITAB), Institute for Innovation, Capacity Building and Sustainability of Agri-Food Production (Inov4Agro), University of Trás-os-Montes and Alto Douro, 5001-801 Vila Real, Portugal.
Antibiotics (Basel). 2024 Sep 21;13(9):904. doi: 10.3390/antibiotics13090904.
: spp. remain a leading cause of bacterial gastroenteritis worldwide, with resistance to antibiotics posing significant challenges to treatment and public health. This study examines profiles in antimicrobial resistance (AMR) for isolates from human and animal sources over the past decade. : We conducted a comprehensive review of resistance data from studies spanning ten years, analyzing profiles in resistance to key antibiotics, ciprofloxacin (CIP), tetracycline (TET), erythromycin (ERY), chloramphenicol (CHL), and gentamicin (GEN). Data were collated from various regions to assess global and regional patterns of resistance. : The analysis reveals a concerning trend of increasing resistance patterns, particularly to CIP and TET, across multiple regions. While resistance to CHL and GEN remains relatively low, the high prevalence of CIP resistance has significantly compromised treatment options for campylobacteriosis. Discrepancies in resistance patterns were observed between human and animal isolates, with variations across different continents and countries. Notably, resistance to ERY and CHL showed regional variability, reflecting potential differences in antimicrobial usage and management practices. : The findings underscore the ongoing challenge of AMR in , highlighting the need for continued surveillance and research. The rising resistance prevalence, coupled with discrepancies in resistance patterns between human and animal isolates, emphasize the importance of a One Health approach to address AMR. Enhanced monitoring, novel treatment strategies, and global cooperation are crucial for mitigating the impact of resistance and ensuring the effective management of -related infections.
[某种细菌]在全球范围内仍是细菌性肠胃炎的主要病因,其对抗生素的耐药性给治疗和公共卫生带来了重大挑战。本研究调查了过去十年中来自人类和动物源的[该细菌]分离株的抗菌药物耐药性(AMR)概况。我们对跨越十年的研究中的耐药性数据进行了全面回顾,分析了对关键抗生素环丙沙星(CIP)、四环素(TET)、红霉素(ERY)、氯霉素(CHL)和庆大霉素(GEN)的耐药性概况。数据来自各个地区,以评估全球和区域的耐药模式。分析揭示了一个令人担忧的趋势,即在多个地区耐药模式不断增加,尤其是对CIP和TET的耐药性。虽然对CHL和GEN的耐药性仍然相对较低,但CIP耐药性的高流行率严重影响了弯曲杆菌病的治疗选择。在人类和动物分离株之间观察到耐药模式的差异,不同大陆和国家之间也存在差异。值得注意的是,对ERY和CHL的耐药性表现出区域差异,反映了抗菌药物使用和管理实践的潜在差异。研究结果强调了[该细菌]中AMR的持续挑战,突出了持续监测和研究的必要性。耐药率的上升,加上人类和动物分离株之间耐药模式的差异,强调了采用“同一健康”方法应对AMR的重要性。加强监测、创新治疗策略和全球合作对于减轻耐药性的影响以及确保有效管理[该细菌]相关感染至关重要。